Biosimilars in Oncology – Thematic Intelligence

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Accessing in-depth insights from the ‘Biosimilars in Oncology’ report will help you:

  • Understand the milestones of biosimilars in oncology, the trends in the market, and the biosimilar value chain.
  • Assess the marketed and pipeline products and their uptake across 8MM.
  • Learn about the percentage of cancer patients treated with biosimilars, the price of the agents compared to their originator, and key opinion leaders’ outlook for the products.
  • Examine the 8MM regulatory landscapes, their market potential, and their available and upcoming biosimilars.
  • Analyze the opportunities, challenges, and unmet needs facing biosimilar uptake and commercially assessing the major current and future players in the field.

How is our ‘Biosimilars in Oncology’ report unique from other reports in the market?

  • The report provides biosimilars in oncology market assessment across multiple regions.
  • The report provides an insight into approaches required to promote biosimilar uptake.
  • Our thematic report answer questions such as:
    • What is the percentage of cancer patients treated with biosimilars in each 8MM country?
    • Which patient groups are more likely to receive these therapies?
    • What is the price of these agents compared to their originator molecule?
    • What is the key opinion leaders’ outlook for the products?
    • How do biosimilar discounts work and how might they affect future uptake?

 We recommend this valuable source of information to anyone involved in:

  • Pharmaceutical Industries (Big Pharma, Small Biotech, Start-ups, etc.),
  • Pharmaceutical Industry Suppliers (e.g., Consulting Companies, CMOs, CDMOs, CROs, Technology Vendors)
  • Consulting and Professional Services (e.g., Investment Companies, Investment Banks, Equity Companies, etc.)
  • Pharma Manufacturers (Innovative, Biotech, Generics, Biosimilars, Rare/Orphan Disease) / Distributors
  • Financial Institutions (Investors in Pharma/Biotech, Pricing Consultancies)/Parallel Trade Organisations
  • Healthcare Organisations (Payers, HTA Bodies, Reimbursement Groups, Government Healthcare Organizations)
  • Clinical Research Organisations (CROs)

To Get a Snapshot of the State of the Biosimilars in Oncology Report

Download a Free Report Sample

Biosimilars in Oncology Thematic Report Overview

The biosimilar market size in the 8MM was $4 billion in 2022 and is expected to achieve a CAGR of more than 9% during 2022-2029. The market growth has increased sharply in the last five years due to the launch of biosimilars such as bevacizumab, rituximab, and trastuzumab in the 8MM, as well as the high adoption of these products. Biosimilars are biological drugs that are similar, but not identical, to their reference or original product. Minor variability between a biosimilar and its reference medicine is allowed. However, biosimilars should not show any clinically meaningful difference from the originator in terms of quality, safety, and efficacy.

Biosimilar Market Outlook, 2022-2029 ($ Billion)

Biosimilar Market Outlook, 2022-2029 ($ Billion)

Buy the Full Report for More Insights into the Biosimilars Market Forecast

Download a Free Report Sample

The Biosimilars in Oncology thematic research report includes the 8MM regulatory landscapes, their market potential, and their available and upcoming biosimilars. Additionally, the report includes the opportunities and challenges facing biosimilar uptake and a commercial assessment of the major players in the field.

Market Size (2022) $4 billion
CAGR (2022-2029) >9%
Historical Period 2018-2023
Forecast Period 2024-2029
Key Regions ·        US

·        5EU

·        Japan

·        China

Key Companies ·        Sandoz

·        Celltrion

·        Amgen

·        Biocon

·        Pfizer

·        Organon

Enquire and Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before purchasing.

Biosimilars in Oncology - Trends

Since biosimilars are complex, large molecules, they are costly to develop. Therefore, biosimilar companies offer limited discounts. However, manufacturers of the reference product offer discounts and may supply new formulations that are more convenient to use, offsetting the available discounts on biosimilars by biosimilar companies.

Additionally, competition in the biosimilars industry has decreased the cost of biosimilars and their reference products. Increasing market competition due to the availability of multiple biosimilars for a single reference product may raise pricing pressures and compel manufacturers to offer significant discounts. Such discount pricing could reduce future commercial incentives to develop biosimilars.

Buy the Full Report for More Trend Insights into the Biosimilars in Oncology Theme

Download a Free Report Sample

Biosimilars in Oncology Market Segmentation by Regions

The oncology biosimilar market is prevalent in the US, 5EU, Japan, and China. Globally, Europe has the highest adoption of biosimilars as many healthcare institutions in the region only prescribe biosimilars. Moreover, in the EU, biosimilars are interchangeable with their reference products or equivalent biosimilars. Healthcare systems in Europe are primarily publicly funded, with scope for payer-driven policies to boost the adoption of biosimilars and contain healthcare expenditures.

Biosimilars in Oncology Market Analysis by Regions, 2023 (%)

Biosimilars in Oncology Market Analysis by Regions, 2023 (%)

Buy the Full Report for More Regional Insights into the Biosimilars in Oncology Theme

Download a Free Report Sample

Biosimilars in Oncology – Competitive Landscape

A few of the key companies offering biosimilars in the oncology sector are Sandoz, Celltrion, Amgen, Biocon, Pfizer, and Organon, among others.

Sandoz: Sandoz is leading in developing, manufacturing, and commercializing of generic and biosimilar medicines. The company offers products to treat cancer, cardiovascular, dermatological, neurological, ophthalmic, respiratory, and infectious diseases, as well as immune disorders. Sandoz was the first company to own an approved biosimilar and has established itself as a main player since then.

Amgen: Amgen Inc. discovers, develops, manufactures, and markets novel human medicines in six focused disease areas, namely cancer, inflammation, cardiovascular disease, nephrology, bone health, and neurological disorders. Amgen leverages its biologic manufacturing expertise to develop biosimilars and has launched often-prescribed biosimilars in oncology.

Biosimilars in Oncology Market Analysis by Companies

Biosimilars in Oncology Market Analysis by Companies

Buy the Full Report for More Company Insights into the Biosimilars in Oncology Theme

Download a Free Report Sample

Key Highlights

Report deliverables include a PowerPoint report

Survey & Clinical trial analysis includes 8 countries

4 KOLs and one payer interviewed

F. Hoffmann-La Roche Ltd
Bristol-Myers Squibb Co
Sanofi
Amgen Inc
Sandoz
Celltrion
Biocon
Pfizer
Organon
Regeneron
Merck & Co

Table of Contents

1. Executive Summary

2. Biosimilars in Oncology Overview

2.1. Biosimilars Overview

2.2. What are Biosimilars According to Regulators?

2.3. Timeline of Oncology Biosimilar Development by Country in the 8MM

3. Value Chain

3.1. Differences Between Generics and Biosimilars

3.2. Differences Between Biosimilarity and Interchangeability

3.3. Drug Rebates Affecting Biosimilar Uptake in the US

4. Trends

4.1. Biosimilar Pricing

4.2. Biosimilar Market Share

4.3. Oncology Biosimilar Uptake in the 8MM

4.4. Biosimilars in Oncology Clinical Trials

5. Market Analysis

5.1. Forecast of Biosimilars in Oncology

5.2. US Biosimilar Market Potential

5.3. 5EU Biosimilar Market Potential

5.4. Japan Biosimilar Market Potential

5.5. China Biosimilar Market Potential

6. Marketed Products

6.1. Biosimilars Approved

6.2. Market Size for Marketed Biosimilars

6.3. Trastuzumab

6.4. Bevacizumab

6.5. Rituximab

6.6. Biosimilars for Supportive Care

7. Pipeline Products

7.1. Biosimilar Pipeline Products in the 8MM

7.2. Upcoming Biosimilars for Marketed Products: Curative Care

7.3. Upcoming Biosimilars for Marketed Products: Supportive Care

7.4. Future Biosimilars in Oncology

8. Regulatory

8.1. Biosimilar Development Overview

8.2. Biosimilar Regulatory in the 8MM

8.3. US Biosimilar Regulatory Pathway

8.4. Regulatory Approval Ex-US

8.5. Difference Between the Biosimilar Ragulatory Pathways in the 8MM

9. Opportunities, Challenges and Unmet Needs

9.1. Potential for Biosimilars of Immune Checkpoint Inhibitors

9.2. Physican Preference for Biosimilars Versus Subcutaenous Formulations

9.3. Physician Hesitancy to Prescribe Biosimilars

9.4. Physician Perspective on Automatic Substitution and Extrapolation

9.5. Factors that Influence Biosimilar Prescription

9.6. Desired Discounts Biosimilars in Oncology

9.7. Expected Changes in Prescription Patterns

9.8. Initiatives to Encourage Future Use of Biosimilars

9.9. Unmet Needs

10. Companies

10.1. Sandoz as a Major Player

10.2. Celltrion as a Major Player

10.3. Amgen as a Major Player

10.4. Biocon as Major Player

10.5. Organon as a Major Player

11. Appendix

12. Contact Us

Frequently asked questions

Biosimilars in Oncology – Thematic Intelligence thematic reports
Currency USD
$7,995

Can be used by individual purchaser only

$23,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Biosimilars in Oncology – Thematic Intelligence was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Biosimilars in Oncology – Thematic Intelligence in real time.

  • Access a live Biosimilars in Oncology – Thematic Intelligence dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.